Flexbumin
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Flexbumin
- Generic name
- ALBUMIN HUMAN
- Manufacturer
- Takeda Pharmaceuticals America, Inc.
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- 79094f4e-5f5c-44d6-b563-d6078eafe83a
- SPL ID
- 14185d93-8688-4431-9f2b-db36e3ef7ec5
- Version
- 14
- Effective date
- 2024-12-18
- Source export date
- 2026-11-13
- Source partition
- 6
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0006-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/a79c47b73cf1c0b9829667844daa083c5114cf268a1839f963bc5617e9060c4f/drug-label-0006-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:20:55
| Harmonized routes |
|---|
| INTRAVENOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 101452 | derived:openfda.application_number |
| application number | BLA101452 | openfda.application_number | |
| brand name | Flexbumin | openfda.brand_name | |
| generic name | ALBUMIN HUMAN | openfda.generic_name | |
| manufacturer name | Takeda Pharmaceuticals America, Inc. | openfda.manufacturer_name | |
| ndc | package | 0944-0495-06 | openfda.package_ndc |
| ndc | package | 0944-0495-05 | openfda.package_ndc |
| ndc | product | 0944-0495 | openfda.product_ndc |
| ndc11 | package | 00944049506 | derived:openfda.package_ndc |
| ndc11 | package | 00944049505 | derived:openfda.package_ndc |
| rxcui | 1741986 | openfda.rxcui | |
| rxcui | 1741420 | openfda.rxcui | |
| spl id | 14185d93-8688-4431-9f2b-db36e3ef7ec5 | id | |
| spl set id | 79094f4e-5f5c-44d6-b563-d6078eafe83a | set_id | |
| unii | ZIF514RVZR | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions (including anaphylactic reactions) have been observed. If hypersensitivity reaction is suspected, discontinue use and implement appropriate standard medical treatment. ( 5.1 ) Under conditions where hypervolemia and/or hemodilution may occur, adjust the dose and rate of infusion to the patient's volume status. When administering large volumes, monitor hemodynamic parameters and ensure adequate substitution of other blood constituents are available (coagulation factors, platelets, and erythrocytes). Monitor electrolyte balance. ( 5.2 ) Closely monitor hemodynamic parameters after administration for evidence of cardiac or respiratory failure, renal failure or increasing intracranial pressure. ( 5.3 ) Monitor blood pressure in trauma patients and postoperative surgery patients in order to detect re-bleeding secondary to clot disruption. ( 5.4 ) Do not dilute with Sterile Water for Injection as this can cause hemolysis in recipients. ( 5.5 ) This product is made from human plasma and may contain infectious agents e.g., viruses and, theoretically, the variant Creutzfeldt-Jakob disease agent. ( 5.6 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions (including anaphylactic reactions) have been observed. Discontinue administration immediately if a hypersensitivity reaction (including anaphylactic type reactions) is suspected. In case of shock, implement standard medical treatment for shock. 5.2 Hypervolemia/Hemodilution Under conditions where hypervolemia and/or hemodilution may occur, adjust dose and rate of infusion to the patient's volume status. Monitor coagulation and hematology parameters when comparatively large volumes are replaced. Ensure adequate substitution of other blood constituents (coagulation factors, platelets, and erythrocytes). Monitor electrolyte status to maintain the electrolyte balance. Discontinue administration at the first clinical signs of cardiovascular overload (e.g., headache, dyspnea, jugular venous distention, rales and abnormal elevations in systemic or central venous blood pressure). Conditions that pose increased risk of hypervolemia and/or hemodilution include, but are not limited to: Heart failure Hypertension Esophageal varices Pulmonary edema Hemorrhagic diathesis Severe anemia Renal failure 5.3 Hemodynamics Closely monitor hemodynamic parameters after administering FLEXBUMIN 5% for evidence of cardiac or respiratory failure, renal failure or increasing intracranial pressure. 5.4 Blood Pressure Monitor blood pressure in trauma patients and postoperative surgery patients resuscitated with FLEXBUMIN 5% in order to detect re-bleeding secondary to clot disruption. 5.5 Hemolysis Do not dilute FLEXBUMIN 5% with Sterile Water for Injection as this can cause hemolysis in recipients. There exists a risk of potentially fatal hemolysis and acute renal failure from the use of Sterile Water for Injection as a diluent for Albumin (Human) [see Dosage and Administration (2.2) ] . 5.6 Transmission of Infectious Agents FLEXBUMIN 5% is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD, have ever been identified for licensed albumin. All infections thought by a physician possibly to have been transmitted by this product should be reported by the physician or other healthcare provider to Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327). The physician should discuss the risks and benefits of this product with the patient.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema. The most serious adverse reactions are hypersensitivity reaction (including anaphylactic reaction) and pulmonary edema. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals U.S.A., Inc. at 1-877-TAKEDA-7 (1-877-825-3327) or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience No sponsor initiated clinical studies have been conducted with FLEXBUMIN 5%. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of FLEXBUMIN 5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been reported in the postapproval use of FLEXBUMIN 5%: Immune System Disorders: Anaphylactic shock, anaphylactic reaction, hypersensitivity/allergic reactions Nervous System Disorders: Headache, dysgeusia Cardiac Disorders: Myocardial infarction, atrial fibrillation, tachycardia Vascular Disorders: Hypotension, flushing Respiratory, Thoracic, and Mediastinal Disorders: Pulmonary edema, dyspnea Gastrointestinal Disorders: Vomiting, nausea Skin and Subcutaneous Tissue Disorders: Urticaria, rash, pruritus General Disorders and Administration Site Conditions: Pyrexia, chills
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.